Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

UBS analyst Ashwani Verma maintained a Hold rating on Biogen today and set a price target of $130.00. The company’s shares opened today at $133.56. Elevate Your Investing Strate ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen Inc. (BIIB) reported $2.65 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 7.3%. EPS of $5.47 for the same period compares to $5.28 a year ago. The ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen, with a price target of $224.00. The company’s shares closed yesterday at $130.13. Do ...

Analysts have given Biogen a total of 11 ratings, with the consensus rating being Outperform. The average one-year price target is $187.27, indicating a potential 46.42% upside.

In February 2025, Biogen Inc. (NASDAQ:BIIB) formed a partnership with Stoke Therapeutics to develop zorevunersen for Dravet ...

Looking at the chart above, BIIB's low point in its 52 week range is $153.62 per share, with $268.295 as the 52 week high point — that compares with a last trade of $156.32.